Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions

About this update from Guangzhou Innogen Pharmaceutical Group Co Ltd Class H

[{"type":"text","content":"SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in overweight and obesity will be presented at the 2026 American Diabetes Association (ADA) Scientific Sessions, to be held from June 5 to 8, 2026, in New Orleans, Louisiana, USA.","length":472,"tagName":"p"},{"type":"text","content":"Presentation Details","length":20,"tagName":"p"},{"type":"text","content":"Poster Title: Efsubaglutide Alfa in Overweight or Obesity: Phase IIb ENLIGHT Study","length":82,"tagName":"p"},{"type":"text","content":"Abstract Number: 2636-P","length":23,"tagName":"p"},{"type":"text","content":"Presentation Time: June 8, 2026, 12:30 PM (Central Time)","length":56,"tagName":"p"},{"type":"text","content":"Presenter: Qinghua Wang, Ph.D., Founder, Chairman and Chief Executive Officer of Innogen","length":88,"tagName":"p"},{"type":"text","content":"Innogen's proprietary Efsubaglutide α met the primary endpoint of the Phase IIb ENLIGHT study conducted in Chinese overweight and obese adults. This randomized, double-blind, placebo-controlled, multicenter study enrolled 200 overweight and obese adults without diabetes to evaluate the efficacy and safety of Efsubaglutide α at doses ranging from 5 to 20 mg for 18 weeks. Results showed that all dose groups experienced significant weight loss from baseline, superior to the placebo group, and the weight loss was positively correlated with the dose. During treatment, patients in the Efsubaglutide α group showed a continuous weight loss trend without a plateau.","length":668,"tagName":"p"},{"type":"text","content":"The study employed a concise and aggressive dose titration protocol (incrementing every 2 weeks to reach the target dose of 20 mg within 6 weeks, covering both QW and Q2W dosing routes). Results showed that after 18 weeks of treatment including titration and maintenance, Efsubaglutide α significantly reduced the weight of participants, with reductions of 10.58% and 9.70% in the QW and Q2W groups, respectively. Meanwhile, the subjects' waist circumference, visceral fat, and liver fat metabolism indicators all showed significant improvement. Notably, the weight loss...

More updates from Guangzhou Innogen Pharmaceutical Group Co Ltd Class H